Lacdene
Brand names,
Lacdene
Analogs
Lacdene
Brand Names Mixture
Lacdene
Chemical_Formula
C33H30N4O2
Lacdene
RX_link
http://www.rxlist.com/cgi/generic2/telmisartan.htm
Lacdene
fda sheet
Lacdene
msds (material safety sheet)
Lacdene
Synthesis Reference
No information avaliable
Lacdene
Molecular Weight
514.617 g/mol
Lacdene
Melting Point
261-263oC
Lacdene
H2O Solubility
Practically insoluble
Lacdene
State
Solid
Lacdene
LogP
7.245
Lacdene
Dosage Forms
Tablets
Lacdene
Indication
For the treatment of hypertension.
Lacdene
Pharmacology
Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.
Lacdene
Absorption
Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).
Lacdene
side effects and Toxicity
Intravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.
Lacdene
Patient Information
Lacdene
Organisms Affected
Humans and other mammals